Have a feature idea you'd love to see implemented?
Let us know!
CAPR Capricor Therapeutics Inc
Price (delayed)
$17.79
Market cap
$808.91M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.02
Enterprise value
$742.18M
Capricor Therapeutics, Inc., is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class cell and exosome-based therapeutics for the treatment and prevention of diseases. Capricor's lead
Highlights
The debt has declined by 32% year-on-year and by 10% since the previous quarter
Capricor Therapeutics's gross profit has surged by 65% YoY but it has decreased by 14% QoQ
CAPR's revenue has surged by 65% year-on-year but it is down by 14% since the previous quarter
Capricor Therapeutics's net income has decreased by 22% QoQ and by 17% YoY
Key stats
What are the main financial stats of CAPR
Market
Valuations
Earnings
Shares outstanding
45.47M
Market cap
$808.91M
Enterprise value
$742.18M
Price to earnings (P/E)
N/A
Price to book (P/B)
8.48
Price to sales (P/S)
25.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.95
Revenue
$23.23M
EBIT
-$34.11M
EBITDA
-$32.76M
Free cash flow
-$38.33M
Per share
Balance sheet
Liquidity
EPS
-$1.02
Free cash flow per share
-$1.16
Book value per share
$2.1
Revenue per share
$0.7
TBVPS
$2.81
Total assets
$92.95M
Total liabilities
$24.69M
Debt
$1.65M
Equity
$68.26M
Working capital
$65.35M
Debt to equity
0.02
Current ratio
4.19
Quick ratio
4.17
Net debt/EBITDA
2.04
Margins
Efficiency
Dividend
EBITDA margin
-141%
Gross margin
100%
Net margin
-146.9%
Operating margin
-155.6%
Return on assets
-57%
Return on equity
-113%
Return on invested capital
-292.2%
Return on capital employed
-47.1%
Return on sales
-146.9%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CAPR stock price
How has the Capricor Therapeutics stock price performed over time
Intraday
-5.97%
1 week
-3.79%
1 month
-13.51%
1 year
509.25%
YTD
263.8%
QTD
16.96%
Financial performance
How have Capricor Therapeutics's revenue and profit performed over time
Revenue
$23.23M
Gross profit
$23.23M
Operating income
-$36.15M
Net income
-$34.11M
Gross margin
100%
Net margin
-146.9%
Capricor Therapeutics's gross profit has surged by 65% YoY but it has decreased by 14% QoQ
CAPR's revenue has surged by 65% year-on-year but it is down by 14% since the previous quarter
The net margin has declined by 43% since the previous quarter but it is up by 29% year-on-year
The company's operating margin fell by 41% QoQ but it rose by 29% YoY
Growth
What is Capricor Therapeutics's growth rate over time
Valuation
What is Capricor Therapeutics stock price valuation
P/E
N/A
P/B
8.48
P/S
25.34
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
31.95
The EPS has declined by 15% since the previous quarter but it rose by 12% year-on-year
CAPR's P/B is 13% lower than its last 4 quarters average of 9.7 but 10% higher than its 5-year quarterly average of 7.7
The price to sales (P/S) is 151% more than the last 4 quarters average of 10.1 but 82% less than the 5-year quarterly average of 142.9
CAPR's revenue has surged by 65% year-on-year but it is down by 14% since the previous quarter
Efficiency
How efficient is Capricor Therapeutics business performance
The ROE has soared by 82% YoY and by 49% QoQ
The ROS has declined by 43% since the previous quarter but it rose by 29% year-on-year
CAPR's ROIC is up by 28% YoY
The ROA has increased by 9% YoY and by 6% QoQ
Dividends
What is CAPR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CAPR.
Financial health
How did Capricor Therapeutics financials performed over time
Capricor Therapeutics's total assets has surged by 150% YoY and by 143% QoQ
The company's total liabilities fell by 37% YoY and by 8% QoQ
The debt is 98% smaller than the equity
The debt to equity has soared by 101% YoY but it has plunged by 88% from the previous quarter
The debt has declined by 32% year-on-year and by 10% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.